Skip to main content
Premium Trial:

Request an Annual Quote

BD Diagnostics Receives FDA Clearance for GBS Assay

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics said today that it has received 510(k) clearance from the US Food and Drug Administration to market its BD Max GBS Assay for Group B Streptococcus on the BD Max System.

GBS is a leading cause of morbidity and mortality among newborns with maternal colonization, a major risk for early onset of GBS disease, according to BD Diagnostics, a segment of Becton Dickinson. The disease, however, is treatable with antibiotics during labor, and the US Centers for Disease Control and Prevention recommends universal prenatal screening for GBS colonization and intrapartum chemoprophylaxis for colonized mothers to prevent transmission to infants.

The current standard of care for prevention of prenatal GBS disease is by screening pregnant women at 35 to 37 weeks by using cultures. Such methods, however, have limited sensitivity, long turnaround time, and depend on highly trained staff to interpret the results, BD said in a statement.

The new assay on the BD Max system can identify GBS in about one hour in Lim broth, and because it automates sample lysis through polymerase chain reaction detection, the system can analyze up to 24 samples in about two and a half hours, the company said.

The BD Max GBS assay is the only fully automated PCR method for detecting GBS from vaginal or rectal swabs after Lim broth selective enrichment, said Steve Young, scientific director for microbiology and virology at TriCore Reference Laboratories, a clinical trial sites.

"As new CDC guidelines emerge to include molecular testing as an alternative to culture for detecting GBS, the BD MAX GBS assay could serve as an efficient, sensitive, and specific option for laboratories desiring to utilize a molecular method," he said.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.